BIOYF (Biosyent) Quality Rank


BIOYF Biosyent Inc BIOYF
98 GF Score
Price $10.28
GF Value $11.68
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Biosyent Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Biosyent Quality Rank Related Terms

BIOYF
98GF Score
Biosyent Inc BIOYF
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biosyent (BIOYF) Overvalued in 2026?

Based on GuruFocus' analysis, Biosyent stock appears to be undervalued. The current stock price of $10.28 is trading 12% below its estimated GF Value™ of $11.68. GuruFocus considers Biosyent to be Modestly Undervalued.

Key valuation signals for BIOYF:

  • Quality Rank:
  • GF Value™: $11.68 vs. price of $10.28 (12% below fair value)
  • GF Score™: 98/100 with 4 warning signs

No single metric tells the full story. See the BIOYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biosyent Business Description

Other Exchanges RX:Canada
Address 2476 Argentia Road, Suite 402, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It markets and delivers a diverse range of healthcare products, including over-the-counter, behind-the-counter, and prescription options. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX Pd, Inofolic, Gelclair, Cathejell, RepaGyn, Proktis-M, and Tibella. The company derives revenue from pharmaceutical and insecticide business. Geographically, it derives maximum revenue from Canada and also has its presence internationally.
98GF Score

Get the complete analysis for BIOYF

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.28
Price
$11.68
GF Value